Literature DB >> 15831840

Rate of reinfection tuberculosis after successful treatment is higher than rate of new tuberculosis.

Suzanne Verver1, Robin M Warren, Nulda Beyers, Madalene Richardson, Gian D van der Spuy, Martien W Borgdorff, Donald A Enarson, Marcel A Behr, Paul D van Helden.   

Abstract

RATIONALE: In a high-tuberculosis (TB) incidence area of Cape Town, South Africa, there is a very high rate of unexplained recurrent TB. The incidence of new bacteriologically confirmed disease in the area is 313 per 100,000 individuals.
OBJECTIVE: To estimate the rate of recurrent TB attributable to reinfection after successful treatment.
METHODS: All patients with reported TB in the area between 1993 and 1998 were followed up to 2001 for disease needing retreatment (recurrences). Patients who were multi-drug-resistant or who had treatment failure, were transferred, or died during treatment were excluded. Analysis was restricted to patients for whom DNA fingerprinting of their Mycobacterium tuberculosis isolates was obtained. Reinfection TB was defined as a recurrent TB episode in which the strains of the separate episodes differed by more than four bands.
MEASUREMENTS AND MAIN RESULTS: 612 of 897 (68%) patients had a DNA fingerprint available at enrollment. Median duration of follow-up was 5.2 years. Recurrent TB occurred in 108 of 612 (18%) patients, of whom 61 of 447 (14%) experienced recurrence after successful treatment, and 47 of 165 (28%) experience recurrence after default. Of the 108 patients with recurrent TB, 68 (63%) had a DNA fingerprint in the second episode. Among these patients, 24 of 31 (77%) recurrences after successful treatment and 4 of 37 (11%) recurrences after default were attributable to reinfection. The reinfection disease rate after successful treatment was estimated at 2.2 per 100 person-years.
CONCLUSIONS: The age-adjusted incidence rate of TB attributable to reinfection after successful treatment was four times that of new TB. People who had TB once are at a strongly increased risk of developing TB when reinfected.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15831840     DOI: 10.1164/rccm.200409-1200OC

Source DB:  PubMed          Journal:  Am J Respir Crit Care Med        ISSN: 1073-449X            Impact factor:   21.405


  144 in total

1.  Beneficial and perverse effects of isoniazid preventive therapy for latent tuberculosis infection in HIV-tuberculosis coinfected populations.

Authors:  Ted Cohen; Marc Lipsitch; Rochelle P Walensky; Megan Murray
Journal:  Proc Natl Acad Sci U S A       Date:  2006-04-21       Impact factor: 11.205

2.  How host heterogeneity governs tuberculosis reinfection?

Authors:  M Gabriela M Gomes; Ricardo Aguas; João S Lopes; Marta C Nunes; Carlota Rebelo; Paula Rodrigues; Claudio J Struchiner
Journal:  Proc Biol Sci       Date:  2012-02-22       Impact factor: 5.349

3.  High burden of prevalent tuberculosis among previously treated people in Southern Africa suggests potential for targeted control interventions.

Authors:  Florian M Marx; Sian Floyd; Helen Ayles; Peter Godfrey-Faussett; Nulda Beyers; Ted Cohen
Journal:  Eur Respir J       Date:  2016-07-07       Impact factor: 16.671

Review 4.  Endobronchial tuberculosis: an overview.

Authors:  Q Xue; N Wang; X Xue; J Wang
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2011-04-16       Impact factor: 3.267

Review 5.  Seventy Years of Tuberculosis Prevention: Efficacy, Effectiveness, Toxicity, Durability, and Duration.

Authors:  Nicole Salazar-Austin; David W Dowdy; Richard E Chaisson; Jonathan E Golub
Journal:  Am J Epidemiol       Date:  2019-12-31       Impact factor: 4.897

6.  The persistence of tuberculosis in the age of DOTS: reassessing the effect of case detection.

Authors:  David W Dowdy; Richard E Chaisson
Journal:  Bull World Health Organ       Date:  2009-04       Impact factor: 9.408

7.  Risk factors and mortality associated with default from multidrug-resistant tuberculosis treatment.

Authors:  Molly F Franke; Sasha C Appleton; Jaime Bayona; Fernando Arteaga; Eda Palacios; Karim Llaro; Sonya S Shin; Mercedes C Becerra; Megan B Murray; Carole D Mitnick
Journal:  Clin Infect Dis       Date:  2008-06-15       Impact factor: 9.079

8.  23-valent pneumococcal polysaccharide vaccine elicits hierarchical antibody and cellular responses in healthy and tuberculosis-cured elderly, and HIV-1-infected subjects.

Authors:  Huichang Huang; Xiaohua Qian; Rong Pan; Ling Shen; Shanshan Liang; Feifei Wang; Peng Zhang; Hongbo Shen; Zheng W Chen
Journal:  Clin Immunol       Date:  2018-05-09       Impact factor: 3.969

Review 9.  Tuberculosis: drug resistance, fitness, and strategies for global control.

Authors:  Erik C Böttger; Burkhard Springer
Journal:  Eur J Pediatr       Date:  2007-11-07       Impact factor: 3.183

10.  The emergence of latent infection in the early evolution of Mycobacterium tuberculosis.

Authors:  Rebecca H Chisholm; Mark M Tanaka
Journal:  Proc Biol Sci       Date:  2016-05-25       Impact factor: 5.349

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.